| __timestamp | Exelixis, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 2983000000 |
| Thursday, January 1, 2015 | 57305000 | 3426000000 |
| Friday, January 1, 2016 | 116145000 | 3398000000 |
| Sunday, January 1, 2017 | 159362000 | 3878000000 |
| Monday, January 1, 2018 | 206366000 | 4056000000 |
| Tuesday, January 1, 2019 | 228244000 | 4381000000 |
| Wednesday, January 1, 2020 | 293355000 | 5151000000 |
| Friday, January 1, 2021 | 401715000 | 5246000000 |
| Saturday, January 1, 2022 | 459856000 | 5673000000 |
| Sunday, January 1, 2023 | 542705000 | 6090000000 |
| Monday, January 1, 2024 | 492128000 | 6091000000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and Exelixis, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Gilead's SG&A expenses have consistently been higher, peaking at approximately $6.1 billion in 2023. In contrast, Exelixis has shown a more conservative trajectory, with expenses rising from $51 million in 2014 to $543 million in 2023.
Despite Gilead's larger scale, Exelixis has managed to keep its SG&A expenses at about 9% of Gilead's, showcasing a leaner operational model. This comparison highlights the strategic differences in cost management between a biotech behemoth and a nimble competitor, offering valuable insights for investors and industry analysts alike.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
BeiGene, Ltd. and Exelixis, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Exelixis, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.